References
- Subak L L, Brown J S, Kraus S R, et al. The ‘costs’ of urinary incontinence for women. Obstet Gynecol 2006; 107: 908–916
- Brown J S, Vittinghoff E, Wyman J F, et al. Grady D urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721–725
- Jolly E E, Bjarnason N H, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10: 337–444
- Davies G C, Huster W J, Lu Y, Plouffe L, Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558–565
- Vardy M D, Lindsay R, Scotti R J, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003; 189: 81–88
- Goldstein S R, Johnson S, Watts N B, Ciaccia A V, Elmerick D, Muram D. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 2005; 12: 160–164
- Waetjen L E, Brown J S, Modelska K, Blackwell T, Vittinghoff E, Cummings S R, MORE Study Group. Effect of raloxifene on urinary incontinence: a randomized controlled trial. Obstet Gynecol 2004; 103: 261–266
- Novo Nordisk drops Levormeloxifene. Script 1998; 23: 18, PJB Publications Limited
- Goldstein S R, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002; 187: 521–527
- Warming L, Christoffersen C, Riis B J, Stakkestad J A, Delmas P D, Christiansen C. Adverse effects of a SERM (levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003; 44: 189–199
- Digesu G A, Khullar V, Cardozo L, Robinson D, Salvatore S. P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 176–181
- FitzGerald M P, Kenton K, Shott S, Brubaker L. Responsiveness of quality of life measurements to change after reconstructive pelvic surgery. Am J Obstet Gynecol 2001; 185: 20–24
- Brown J S, Grady D, Ouslander J G, Herzog A R, Varner R E, Posner S F. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999; 94: 66–70
- Rogers R G. The vexing problem of hidden incontinence. N Engl J Med 2006; 354: 1627–1629
- Teleman P M, Lidfeldt J, Nerbrand C, Samsioe G, Mattiasson A, WHILA study Group. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. Br J Obstet Gynaecol 2004; 111: 600–604
- McGrother C W, Donaldson M M, Hayward T, Matthews R, Dallosso H M, Hyde C, The Leicestershire MRC Incontinence Study Team. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006; 35: 16–24
- MacLennan A H, Taylor A W, Wilson D H, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. Br J Obstet Gynaecol 2000; 107: 1460–1470